// App-Quantinova.ai

3506 : Carfilzomib demonstrates antiproliferative and proapoptotic activities in preclinical triple-negative breast cancer models

Researchers

Presenter

  • Mathew Larson

Principal Investigators

  • Jennifer H. Carlson

  • Yuliang Sun

  • Tonia Bucholz

  • Casey Williams

  • Nandini Dey

  • Brian Leyland-Jones

  • Pradip De

Medical Centers

  • Avera Research Institute, Sioux Falls, SD.

  • Threshold Pharmaceuticals, Inc., South San Francisco, CA

Locations

  • United States

Companies

  • Onyx Pharmaceuticals

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Triple-negative breast cancer

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Myeloid Cell Leukemia 1

  • BCL2 like 11

  • Proliferation marker protein Ki-67

Drug/Treatment

  • carfilzomib Intravenous

  • Sapanisertib

  • ribose

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved